Valvular & structural heart diseaseRandomised controlled trial
Estimating the Effects of Mitral Transcatheter Edge-to-edge Repair (MTEER) in U.S. Practice
- Transportability analysis of the COAPT randomised trial to US registry populations
- inverse odds of participation weighting
- Transcatheter Valve Therapy (TVT) Registry
Authors' conclusion
Although COAPT trial patients had different baseline characteristics than patients undergoing MTEER in contemporary U.S. practice, we estimated that treatment effects would be similar had real-world patients received COAPT trial interventions, under the assumptions required for transportability (eg, conditional exchangeability across data sources, positivity of trial participation).
Study context
- Population
- Patients treated with MTEER for secondary mitral regurgitation, STS/ACC TVT Registry, March 14, 2019 to September 30, 2023; trial-eligible and treatment-candidate target populations614 COAPT + 15,275 TVT Registry patients
- Comparison
- MTEER plus COAPT interventions vs medical therapy alone
- Primary endpoint
- HF hospitalization
- Follow-up
- 2 years
Primary result
HF hospitalization, trial-eligible population
Absolute risk reduction
17.0%
95% CI −28.7% to −5.7%
As reported in the abstract
Secondary outcomes
| Outcome | absolute risk reduction (95% CI) |
|---|---|
| All-cause death, trial-eligible population · 2 years · similar to trial (P for difference >0.05) | 15.4% (−26.6% to −5.2%) |
HF hospitalization, treatment-candidate population
- Treatment effect similar to that in the COAPT trial
- P for difference = 0.90
Original publication
Estimating the Effects of MTEER in U.S. Practice. J Am Coll Cardiol. Published 3 June 2026. doi:10.1016/j.jacc.2026.04.025
Summarised from the published abstract; every number is checked against it